Non-small cell lung cancer brain metastases and the immune system: from brain metastases development to treatment
Brain metastases (BM) are diagnosed in approximately 40% of non-small cell lung cancer (NSCLC) patients during the course of their disease [1]. They are a poor prognostic factor and can have a negative impact on quality of life (QoL) [2 –4]. Depending on symptoms, number, size and locations of the BM, patients can be treated locally with stereotactic radiotherapy (SRT), surgery or whole brain radiation (WBRT) [5]. In those with neurologically asymptomatic BM another option is upfront systemic treatment (targeted treatment or chem otherapy) [5,6].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Elie El Rassy, Angela Botticella, Joseph Kattan, Cecile Le P échoux, Benjamin Besse, Lizza Hendriks Tags: Anti-Tumour Treatment Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Lung Cancer | Neurology | Neurosurgery | Non-Small Cell Lung Cancer